NCT00591422View on ClinicalTrials.gov

Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-Hodgkin's Lymphomas

PHASE1UnknownINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions

Advanced Cancer

Interventions

DRUG

ZIO-101-C (Darinaparsin)

Capsule, Dose escalation study from 100 mg to 1000 mg (or Maximum Tolerated Dose). 3 times weekly (\>36 hours between doses) for 3 weeks with 1 week rest.

Trial Locations (3)

23502

Norfolk

34761

Ocoee

75246

Dallas